 Moderna Inc NASDAQ: MRNA has tanked nearly 15 in recent days but a Jefferies analyst dubs it one of his best ideas for 2023. Moderna stock could climb another 50 Earlier in December, the biotech company said its candidate vaccine for skin cancer showed encouraging results in a Phase II study read more. 